ST
RXRX icon

Smithfield Trust’s Recursion Pharmaceuticals RXRX Stock Holding History

Smithfield Trust’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,099
Closed -$11K – 1075
2024
Q1 		$11K Hold
1,099
– – ﹤0.01% 825
2023
Q4 		$11K Hold
1,099
– – ﹤0.01% 818
2023
Q3 		$8K Buy
+1,099
New +$11K ﹤0.01% 840

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smithfield Trust's RXRX Position: Q2 2024 in Review

Smithfield Trust sold out of Recursion Pharmaceuticals (RXRX) in Q2 2024, closing a stake of 1,099 shares — an estimated $11K sold.

Smithfield Trust first reported a position in RXRX in Q3 2023 and held it in 3 quarters. The position peaked at $11K in Q1 2024. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

  • Smithfield Trust reported no remaining Recursion Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Smithfield Trust sold 1,099 Recursion Pharmaceuticals shares in Q2 2024, an estimated $11K.
  • Smithfield Trust first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Smithfield Trust's Recursion Pharmaceuticals position peaked at $11K in Q1 2024.
  • 270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Smithfield Trust's 13F filing for Q2 2024, filed 31 Jul 2024.